FDA OKs expanded use of Teva's ProAir RespiClick

• The FDA approves the use of Teva Pharmaceutical Industries' (NYSE:TEVA) ProAir RespiClick (albuterol sulfate) Inhalation Powder for the treatment or prevention of bronchospasm in children 4 to 11 years old with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.
• ProAir was approved by the FDA 13 months ago for use in patients at least 12 years old.